IL23R and inflammatory bowel disease: In a retrospective study of 90 moderate-to-severe patients with UC treated with IFX induction therapy, those who were homozygous for IBD risk-increasing IL23R variants (rs1004819, rs2201841, rs10889677, rs11209032, rs1495965) showed a significantly higher probability of responding to IFX at 14 weeks than those who were homozygous for risk-decreasing IL23R variants (rs7517847, rs10489629, rs11465804, rs1343151) (74.1% versus 34.6%, p = 0.001) [138].